Diagnostic value of [18F]FDG PET for differential diagnosis of pseudo-dementia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00035787

Enrollment

100

Registered

2025-01-02

Start date

2023-02-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F33.2

Interventions

Group 1: 75-100 geratric-psychiatric patients with depression and cognitive deficits, who were reffered for hospital treatment and [18F]FDG PET imaging

Eligibility

Sex/Gender

All

Age

No minimum to 50 Years

Inclusion criteria

Inclusion criteria: clinically verified cognitive deficit as ascertained by neuropsychlogical testing (i.e. MOCA cut off =7 points) technically sufficiant [18F]FDG PET between 1.1.2018 and 30.11.2022 in the Klinik für Nuklearmedizin des UKF Treatment in the Klinik für Psychiatrie und Psychotherapie des UKF

Exclusion criteria

Exclusion criteria: if one of the inclusion criteria is not fulfilled study exclusion is the consequence

Design outcomes

Primary

Measure	Time frame
retrospective evaluation of diagnostic value of [18F]FDG PET in the following subgroups matched for age, gender and results of neuropsychological testing (i.e. MMST or MOCA): "cognitive deficits due to neurodegenerative disorder with/without depression" defined by best lifetime diagnosis versus "cognitive deficits due to depression" defined by best lifetime diagnosis using statistical models (i.e. regression analysis, ANCOVA)	—

Measure

Time frame

retrospective evaluation of diagnostic value of [18F]FDG PET in the following subgroups matched for age, gender and results of neuropsychological testing (i.e. MMST or MOCA): "cognitive deficits due to neurodegenerative disorder with/without depression" defined by best lifetime diagnosis versus "cognitive deficits due to depression" defined by best lifetime diagnosis using statistical models (i.e. regression analysis, ANCOVA)

—

Secondary

Measure	Time frame
Evaluation of the predicitive value of [18F]FDG PET for survival in patients with a neurodegenerative dementia vs. depressive patients	—

Countries

Germany

Contacts

Public ContactSabine Hellwig

Klinik für Psychiatrie und Psychotherapie, Uniklinik Freiburg

sabine.hellwig@uniklinik-freiburg.de4976127065010

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026